What is HC Wainwright’s Forecast for TARA FY2029 Earnings?

Protara Therapeutics, Inc. (NASDAQ:TARA) – Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Protara Therapeutics in a note issued to investors on Thursday, March 6th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.73) per share for the year. HC Wainwright has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09.

Separately, Guggenheim reissued a “buy” rating and issued a $20.00 target price on shares of Protara Therapeutics in a research report on Friday, December 6th.

Protara Therapeutics Stock Up 2.6 %

Shares of NASDAQ TARA opened at $4.02 on Friday. The firm has a market cap of $82.93 million, a price-to-earnings ratio of -1.43 and a beta of 1.69. Protara Therapeutics has a 52-week low of $1.60 and a 52-week high of $10.48. The business’s 50 day moving average is $4.56 and its two-hundred day moving average is $3.42.

Institutional Trading of Protara Therapeutics

A number of large investors have recently modified their holdings of the stock. RA Capital Management L.P. increased its position in shares of Protara Therapeutics by 78.9% during the fourth quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock worth $17,952,000 after acquiring an additional 1,500,000 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of Protara Therapeutics during the fourth quarter worth $11,938,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Protara Therapeutics during the fourth quarter worth $11,880,000. Toronto Dominion Bank purchased a new stake in shares of Protara Therapeutics during the fourth quarter worth $11,030,000. Finally, Blackstone Inc. purchased a new position in Protara Therapeutics in the fourth quarter valued at $8,870,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.